v3.25.1
CONVERTIBLE DEBT (Details Narrative) - Aspire Biopharma Inc [Member] - USD ($)
Feb. 13, 2025
Feb. 07, 2025
Jan. 22, 2025
Feb. 17, 2025
Dec. 31, 2024
Dec. 30, 2024
Oct. 02, 2024
Sep. 27, 2024
Dec. 31, 2023
Convertible debt         $ 0       $ 0
Indebtedness amount         279,878 $ 40,625 $ 62,500 $ 1,066,391  
Original issuance discounts         $ 46,646 $ 8,125 $ 12,500 $ 213,278  
Subsequent Event [Member]                  
Stockholders equity reverse stock split   Company’s board of directors voted unanimously to a 15.9538267 for 1 reverse split              
Business combination of outstanding common shares   531,822,059              
Subsequent Event [Member] | Purchase Agreement [Member] | Arena Business Solutions Global SPC II Ltd [Member]                  
Number of shares issued 100,000,000                
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Cobra Alternative Capital Strategies LLC [Member]                  
Derivative, Notional Amount       $ 3,750,000          
Derivative, Average Variable Interest Rate       92.50%          
Derivative, Floor Interest Rate       4.00%          
Subsequent Event [Member] | Non Convertible 20 % OlD Note Payable [Member]                  
Indebtedness amount     $ 31,250            
Gross proceeds     $ 2,500,000            
Exit fee percentage     5.00%            
Original issuance discounts     $ 6,250